CytoReason Disease Model

The CytoReason Disease Model is an AI-powered computational platform designed to map and compare treatments, patient groups, and disease mechanisms across multiple indications. Built for pharmaceutical and biotech organizations engaged in drug discovery and precision medicine, it is the first model of its kind to provide a transparent, multi-layered view of human disease — explicitly positioned as not a black box. The platform is created by top immunologists and backed by top-tier scientific publications, making it a rigorous and credible foundation for translational research.

CytoReason operates on the principle that the complexity of human disease demands full use of all available data. The platform continuously integrates public and proprietary datasets, ensuring models are ever-growing and ever-updated to reflect the latest clinical and molecular insights.

Core Workflow: Collect, Capture, Compare

• Collect: Access ever-growing disease models and retrieve the latest clinical data from multiple indications and treatments.
• Capture: Understand the different layers of disease using innovative tools including cell-level analysis and network analysis.
• Compare: Manage drug portfolios using all relevant comparisons across patients, indications, and treatments.

Model Layers and Capabilities

• Datasets and Literature: Build on the latest omics data combined with cell-focused natural language processing (NLP) to incorporate findings from scientific literature.
• Cell State: Obtain each cell's specific regulatory program to understand cellular behavior at a granular level.
• Disease Progression: Identify and understand the drivers of disease changes over time.
• Clinical Variation: Characterize disease variation between individual patients, supporting precision medicine approaches.
• Cell Composition: Monitor cytometry, single-cell, and deconvolved expression data to retain and leverage cellular information throughout analysis.
• Inter-cellular Tissue Network: Model cell-to-cell interactions based on biological features within the tissue microenvironment.
• Treatments: Understand and compare the effects of different treatments on the overall disease landscape.

Key Differentiators

• The latest and greatest: Developed by leading immunologists and supported by top-tier peer-reviewed publications.
• Highly specific: Models are broken down by disease and tissue type, and further stratified by patient population and disease severity.
• Inside Out: Every disease layer is linked to its clinical and molecular features, with integrated tools for cell-level and network analysis providing a fully connected view.
• Bigger and better data: The platform is continuously expanded and updated with both public and proprietary data sources.

Validated Through Industry Collaborations

• CytoReason partnered with Ferring Research Institute on AI-driven novel target identification for inflammatory bowel disease (IBD), combining CytoReason's cell-centered AI technology with Ferring's deep therapeutic expertise.
• Sanofi expanded its collaboration with CytoReason to describe diseases at the molecular and cellular level, aiming to understand differential patient responses to treatments and match the right medicine to the right patient, with a focus on IBD.
• Poolbeg Pharma collaborated with CytoReason to identify multiple novel influenza drug targets, reporting accelerated research activity, reduced costs, and new possibilities for target identification and drug development.

CytoReason's platform supports integration of proprietary partner data alongside its existing disease models, enabling life sciences organizations to bring their own data to life within a richly contextualized, cell-centered AI framework.